NYQ·Healthcare·$442M·#218 / 520 in Healthcare
EBS Emergent BioSolutions Inc.
50SPECULATIVE
CATEGORY BREAKDOWN
GROWTH0
QUALITY49
STABILITY69
VALUATION100
GOVERNANCE43
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
-30.4%
0
> 50% strong
Gross Margin
Revenue retained after direct costs
53.7%
76
> 50% strong
Cash Runway
Months of cash at current burn rate
999 months
100
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
109.5%
8
< 25% strong
Price / Sales
Market cap relative to trailing revenue
0.7x
100
< 3x strong
Rule of 40
Growth rate plus operating margin
-15
9
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
1.9%
15
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
-14.2%
100
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE EBS WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when EBS's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.